464 related articles for article (PubMed ID: 15531767)
1. Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
Braunwald E; Domanski MJ; Fowler SE; Geller NL; Gersh BJ; Hsia J; Pfeffer MA; Rice MM; Rosenberg YD; Rouleau JL;
N Engl J Med; 2004 Nov; 351(20):2058-68. PubMed ID: 15531767
[TBL] [Abstract][Full Text] [Related]
2. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.
Køber L; Torp-Pedersen C; Carlsen JE; Bagger H; Eliasen P; Lyngborg K; Videbaek J; Cole DS; Auclert L; Pauly NC
N Engl J Med; 1995 Dec; 333(25):1670-6. PubMed ID: 7477219
[TBL] [Abstract][Full Text] [Related]
3. [Peace-study. Coronary heart disease: additive therapy with ACE-inhibitors?].
Böhm M
Internist (Berl); 2005 May; 46(5):592-4. PubMed ID: 15834542
[No Abstract] [Full Text] [Related]
4. ACE inhibition in secondary prevention: are the results controversial?
Friedrich EB; Teo KK; Böhm M
Clin Res Cardiol; 2006 Feb; 95(2):61-7. PubMed ID: 16598512
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
Fox KM;
Lancet; 2003 Sep; 362(9386):782-8. PubMed ID: 13678872
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S
Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study.
Torp-Pedersen C; Køber L; Carlsen J
Am Heart J; 1996 Jul; 132(1 Pt 2 Su):235-43. PubMed ID: 8677862
[TBL] [Abstract][Full Text] [Related]
8. New considerations relating to class effect with angiotensin-converting enzyme inhibitors--the PEACE study.
Sica DA
J Clin Hypertens (Greenwich); 2005 Mar; 7(3):188-93. PubMed ID: 15785163
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
[TBL] [Abstract][Full Text] [Related]
10. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
; Yusuf S; Sleight P; Pogue J; Bosch J; Davies R; Dagenais G
N Engl J Med; 2000 Jan; 342(3):145-53. PubMed ID: 10639539
[TBL] [Abstract][Full Text] [Related]
11. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).
Kjøller-Hansen L; Steffensen R; Grande P
J Am Coll Cardiol; 2000 Mar; 35(4):881-8. PubMed ID: 10732883
[TBL] [Abstract][Full Text] [Related]
12. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
Shah AD; Arora RR
Clin Cardiol; 2005 Dec; 28(12):551-5. PubMed ID: 16405197
[TBL] [Abstract][Full Text] [Related]
13. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
Solomon SD; Rice MM; A Jablonski K; Jose P; Domanski M; Sabatine M; Gersh BJ; Rouleau J; Pfeffer MA; Braunwald E;
Circulation; 2006 Jul; 114(1):26-31. PubMed ID: 16801465
[TBL] [Abstract][Full Text] [Related]
14. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.
Rouleau JL; Warnica WJ; Baillot R; Block PJ; Chocron S; Johnstone D; Myers MG; Calciu CD; Dalle-Ave S; Martineau P; Mormont C; van Gilst WH;
Circulation; 2008 Jan; 117(1):24-31. PubMed ID: 18071079
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.
Udell JA; Morrow DA; Jarolim P; Sloan S; Hoffman EB; O'Donnell TF; Vora AN; Omland T; Solomon SD; Pfeffer MA; Braunwald E; Sabatine MS
J Am Coll Cardiol; 2014 Jun; 63(22):2421-8. PubMed ID: 24727254
[TBL] [Abstract][Full Text] [Related]
16. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation.
Torp-Pedersen C; Køber L
Lancet; 1999 Jul; 354(9172):9-12. PubMed ID: 10406358
[TBL] [Abstract][Full Text] [Related]
17. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders.
Peters DC; Noble S; Plosker GL
Drugs; 1998 Nov; 56(5):871-93. PubMed ID: 9829159
[TBL] [Abstract][Full Text] [Related]
18. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy.
Mitchell GF; Dunlap ME; Warnica W; Ducharme A; Arnold JM; Tardif JC; Solomon SD; Domanski MJ; Jablonski KA; Rice MM; Pfeffer MA;
Hypertension; 2007 Jun; 49(6):1271-7. PubMed ID: 17452505
[TBL] [Abstract][Full Text] [Related]
19. Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition.
Pfeffer MA; Domanski M; Rosenberg Y; Verter J; Geller N; Albert P; Hsia J; Braunwald E
Am J Cardiol; 1998 Aug; 82(3A):25H-30H. PubMed ID: 9719019
[TBL] [Abstract][Full Text] [Related]
20. Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials.
Young JB
Cardiovasc Drugs Ther; 1995 Feb; 9(1):89-102. PubMed ID: 7786840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
